Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Patrick Kugel"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/c6ee87f14cf14e878f7c4b1837259a12
Autor:
Patrick Kugel, Leisha A. Emens, Kinjal Parikh, Ann Carothers, Haleh Kadkhoda, Charlotte Warren
Publikováno v:
Cancer Research. 81:PS9-15
Background:Immunotherapy was first introduced into the treatment of triple negative breast cancer with the approval of nab-paclitaxel + atezolizumab in patients with metastatic PD-L1-positive disease. Continued research sheds light on the utility of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19627b7fb3cd7df6b4a0e21ecad55bfb
https://doi.org/10.1158/1538-7445.sabcs20-ps9-15
https://doi.org/10.1158/1538-7445.sabcs20-ps9-15
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Advanced melanoma treatment selection is guided by BRAF-mutation status and patient and disease-specific factors. Historically, oncologists decided between targeted therapy or immune checkpoint inhibitors (ICI). However, given the differen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42eaadd4720e8e7d4ecb0185c43295f3
https://doaj.org/article/c6ee87f14cf14e878f7c4b1837259a12
https://doaj.org/article/c6ee87f14cf14e878f7c4b1837259a12
Autor:
Emily Sherene Van Laar, Donna L. Topping, Saee Dhoble, Kinjal Parikh, Haleh Kadkhoda, Patrick Kugel, Jacob Cohen
Publikováno v:
Journal of Clinical Oncology. 39:492-492
492 Background: Immunotherapy (IO) utility in bladder cancer (UC) has expanded into multiple stages of disease. Employing IO optimally requires mastery of clinical trial data, patient eligibility criteria, and interpretation of biomarkers and determi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42e945893ceb4567ea11729a1a120c53
https://doi.org/10.1200/jco.2021.39.6_suppl.492
https://doi.org/10.1200/jco.2021.39.6_suppl.492
Publikováno v:
Journal of Clinical Oncology. 39:347-347
347 Background: Chemotherapy is a mainstay treatment modality for patients with advanced cholangiocarcinoma (CCA). Recent developments and new approvals have led to changing paradigms, incorporating the use of targeted therapies for patients with pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1943b2a2d34ade1b75e8f2406215ea1
https://doi.org/10.1200/jco.2021.39.3_suppl.347
https://doi.org/10.1200/jco.2021.39.3_suppl.347
Autor:
Patrick Kugel, Kinjal Parikh, Charlotte Warren, Haleh Kadkhoda, Emily Sherene Van Laar, Katie S. Lucero
Publikováno v:
Journal of Clinical Oncology. 39:479-479
479 Background: Gastrointestinal (GI) cancers are a heterogeneous group of cancers with varying underlying pathophysiology and distinct treatment paradigms. Immunotherapy (IO) is unique in each of the subtypes and biomarkers utility varies. With the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04231cddaa71cd6d54324c705a2300c2
https://doi.org/10.1200/jco.2021.39.3_suppl.479
https://doi.org/10.1200/jco.2021.39.3_suppl.479
Autor:
Farrukh T. Awan, Patrick Kugel, Katie S. Lucero, Lauren Willis, Jacqueline C. Barrientos, John N. Allan, Emily S Van Laar, Lisa Brauer, Danielle M. Brander, Jonathon B. Cohen
Publikováno v:
Blood. 134:5878-5878
Introduction: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western world. Treatment selection in CLL is dependent upon a number of factors, such as patient age and genetic mutations, and can be challenging. A number of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a160c9097edb3d62b8e5e4a88b0bd223
https://doi.org/10.1182/blood-2019-124808
https://doi.org/10.1182/blood-2019-124808